Product image of Nuvaring (Ethinylestradiol, Etonogestrel) supplied by GNH India

Nuvaring

Active Ingredient:
Ethinylestradiol, Etonogestrel
Origin:
EU

Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol and etonogestrel, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a 0.015 mg/day ethinylestradiol and 0.12 mg/day etonogestrel vaginal ring for vaginal use. It prevents pregnancy in women of reproductive age by providing continuous hormone delivery throughout a three‑week cycle.

GNH India supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable supply for global contraceptive programs.

Manufacturer / TM Owner

Organon Belgium B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • NuvaRing, a combined estrogen‑progestogen contraceptive, is indicated for hormonal contraception.
  • Prevention of pregnancy: provides effective reversible contraception for women of reproductive age.
  • Hormonal birth control: delivers continuous estrogen and progestogen to suppress ovulation.
  • Cycle regulation: helps maintain a predictable menstrual cycle while preventing conception.

How It Works

  • NuvaRing releases ethinylestradiol and etonogestrel locally into the vaginal mucosa, where the estrogen component stabilizes the endometrial lining and the progestogen component binds progesterone receptors in the hypothalamus and pituitary. This dual action suppresses the mid‑cycle luteinizing hormone surge, preventing ovulation, while also thickening cervical mucus and altering the endometrium, creating multiple barriers to fertilization and implantation.

Side Effects

NuvaRing may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache episodes.
  • Nausea: occasional nausea or stomach upset.
  • Vaginal irritation: discharge, itching or discomfort at the insertion site.
  • Breast tenderness: mild swelling or tenderness of the breasts.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Hepatic dysfunction: jaundice or abnormal liver enzymes.
  • Allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

Before prescribing NuvaRing, clinicians should consider several safety and handling precautions.

  • Smoking status: avoid use in women who smoke cigarettes and are over 35 years old.
  • Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction.
  • Migraine history: contraindicated in patients with migraine with aura.
  • Liver disease: use with caution in severe hepatic impairment.
  • Medication adherence: ensure correct insertion and removal schedule to maintain efficacy.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

NuvaRing can interact with other medicines, altering its contraceptive effectiveness or increasing adverse event risk.

Major Interactions (Avoid)

  • Enzyme inducers: carbamazepine, phenytoin, rifampicin may reduce hormone levels.
  • Antifungal azoles: ketoconazole can increase hormone concentrations, raising side‑effect risk.
  • Certain antibiotics: long‑term use of rifampin may compromise contraceptive efficacy.

Moderate Interactions (Monitor Closely)

  • Antidepressants: sertraline may slightly affect hormone metabolism.
  • Antihypertensives: beta‑blockers may have additive effects on blood pressure.

Frequently Asked Questions

NuvaRing is a prescription vaginal contraceptive ring that provides hormonal birth control. It is used to prevent pregnancy in women of reproductive age by delivering a steady dose of estrogen and progestogen over a three‑week period, followed by a one‑week ring‑free interval.

The two hormones act together to suppress the mid‑cycle surge of luteinizing hormone, which prevents ovulation. Ethinylestradiol stabilises the uterine lining, while etonogestrel thickens cervical mucus and alters the endometrium, creating multiple barriers to fertilisation and implantation.

The dosing regimen is set by the prescribing clinician. Typically, a single NuvaRing is inserted into the vagina and left in place for three weeks, then removed for a one‑week ring‑free interval before a new ring is inserted.

NuvaRing is contraindicated during pregnancy (Category X) and should not be started in women who are already pregnant. While limited data exist for breastfeeding, most guidelines advise against using hormonal contraceptive rings during lactation without medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with combined oral contraceptive pills, NuvaRing offers a once‑monthly insertion, which can improve adherence for some users. Both deliver the same hormones, but the ring provides a more stable serum concentration and eliminates daily pill taking, while still sharing similar efficacy and safety profiles.

Store NuvaRing at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme heat. Do not refrigerate or freeze the device, as temperature extremes can affect hormone stability.

A healthcare professional or the user inserts the flexible ring into the upper vaginal canal, ensuring it is placed correctly. The ring remains in place for three weeks, after which it is removed and discarded. A new ring is then inserted after a one‑week break.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, hepatic dysfunction presenting as jaundice or abnormal liver enzymes, and severe allergic reactions that may cause rash, swelling or anaphylaxis. Prompt medical attention is required if any of these occur.

NuvaRing is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or migraine with aura. It should also be avoided by smokers over 35 years of age and anyone with known hypersensitivity to its ingredients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Etonogestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT